Integra Lifesciences Holdings Corp (NASDAQ:IART) Director Stuart Essig sold 140,000 shares of Integra Lifesciences Holdings Corp stock in a transaction that occurred on Tuesday, May 23rd. The stock was sold at an average price of $48.01, for a total value of $6,721,400.00. The sale was disclosed in a filing with the SEC, which is available at this link.

Shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) traded up 1.67% during trading on Wednesday, reaching $48.77. The company’s stock had a trading volume of 439,956 shares. Integra Lifesciences Holdings Corp has a 52-week low of $35.76 and a 52-week high of $48.86. The stock has a 50-day moving average of $44.44 and a 200-day moving average of $54.34. The stock has a market cap of $3.69 billion, a P/E ratio of 58.06 and a beta of 0.80.

Integra Lifesciences Holdings Corp (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, April 26th. The life sciences company reported $0.39 earnings per share for the quarter, missing the consensus estimate of $0.40 by $0.01. Integra Lifesciences Holdings Corp had a net margin of 6.09% and a return on equity of 16.11%. The firm had revenue of $258.60 million for the quarter, compared to the consensus estimate of $254.19 million. During the same period last year, the company posted $0.38 earnings per share. Integra Lifesciences Holdings Corp’s revenue for the quarter was up 9.2% on a year-over-year basis. Analysts predict that Integra Lifesciences Holdings Corp will post $1.92 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Integra Lifesciences Holdings Corp (NASDAQ:IART)

ILLEGAL ACTIVITY WARNING: “Integra Lifesciences Holdings Corp (IART) Director Sells $6,721,400.00 in Stock” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/05/24/integra-lifesciences-holdings-corp-iart-director-sells-6721400-00-in-stock.html.

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its position in shares of Integra Lifesciences Holdings Corp by 307,726.8% in the first quarter. BlackRock Inc. now owns 7,455,564 shares of the life sciences company’s stock valued at $314,104,000 after buying an additional 7,453,142 shares during the period. Vanguard Group Inc. raised its position in Integra Lifesciences Holdings Corp by 116.7% in the first quarter. Vanguard Group Inc. now owns 5,656,048 shares of the life sciences company’s stock worth $238,289,000 after buying an additional 3,046,488 shares during the last quarter. Champlain Investment Partners LLC raised its position in Integra Lifesciences Holdings Corp by 125.2% in the first quarter. Champlain Investment Partners LLC now owns 4,438,760 shares of the life sciences company’s stock worth $187,005,000 after buying an additional 2,468,145 shares during the last quarter. FMR LLC raised its position in Integra Lifesciences Holdings Corp by 44.1% in the first quarter. FMR LLC now owns 7,615,884 shares of the life sciences company’s stock worth $320,857,000 after buying an additional 2,329,710 shares during the last quarter. Finally, Janus Capital Management LLC raised its position in Integra Lifesciences Holdings Corp by 311.6% in the first quarter. Janus Capital Management LLC now owns 2,107,875 shares of the life sciences company’s stock worth $88,803,000 after buying an additional 1,595,705 shares during the last quarter. 44.37% of the stock is owned by institutional investors and hedge funds.

IART has been the subject of several research reports. Oppenheimer Holdings Inc. set a $54.00 price target on Integra Lifesciences Holdings Corp and gave the stock a “buy” rating in a report on Monday, May 15th. Jefferies Group LLC lifted their price target on Integra Lifesciences Holdings Corp from $50.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, April 28th. ValuEngine cut Integra Lifesciences Holdings Corp from a “buy” rating to a “hold” rating in a report on Tuesday. Piper Jaffray Companies reissued an “overweight” rating and set a $47.00 price target on shares of Integra Lifesciences Holdings Corp in a report on Wednesday, March 22nd. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $48.00 price target (up from $46.00) on shares of Integra Lifesciences Holdings Corp in a report on Tuesday, May 2nd. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Integra Lifesciences Holdings Corp currently has a consensus rating of “Buy” and an average target price of $48.83.

Integra Lifesciences Holdings Corp Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

12 Month Chart for NASDAQ:IART

Receive News & Ratings for Integra Lifesciences Holdings Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences Holdings Corp and related companies with MarketBeat.com's FREE daily email newsletter.